Glucose transporter-1 distribution in fibrotic lung disease: Association with [18F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization

Chest

Volumn 143, Issue 6, 2013, Pages 1685-1691

  El Chemaly, Souheil ^a,d   Malide, Daniela ^a   Yao, Jianhua ^b   Nathan, Steven D ^e   Rosas, Ivan O ^a,d   Gahl, William A ^c   Moss, Joel ^a   Gochuico, Bernadette R ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1;

ADULT; ARTICLE; CELL SURFACE; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; FIBROSING ALVEOLITIS; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INFLAMMATORY CELL; LUNG ALVEOLUS CELL CARCINOMA; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOMA; LUNG PARENCHYMA; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; UPREGULATION;

EID: 84878527552     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1359     Document Type: Article

References (30)

1. Brantly M, Avila NA, Shotelersuk V, Lucero C, Huizing M, Gahl WA. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest. 2000;117(1):129-136.
2. Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium . Chest. 2011;140(1):221-229.
3. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest. 2007;132(4):1311-1321.
4. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
5. El-Chemaly S, Malide D, Zudaire E, et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms. Proc Natl Acad Sci U S A. 2009;106(10):3958-3963.
6. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet. 2008;9:359-386.
7. Cullinane AR, Curry JA, Carmona-Rivera C, et al. A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak Syndrome type 9. Am J Hum Genet. 2011;88(6):778-787.
8. Gahl WA, Huizing M. Hermansky-Pudlak Syndrome. 2000 Jul 24 [updated 2010 Jul 08]. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, eds. GeneReviews [Internet]. Seattle WA: University of Washington, Seattle. http://www.ncbi.nlm. nih.gov/books/NBK1287/
9. Gochuico BR, Huizing M, Golas GA, et al. Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease. Mol Med. 2012;18(1):56-64.
10. Thomas de Montpréville V, Mussot S, Dulmet E, Dartevelle P. Pulmonary fibrosis in Hermansky-Pudlak syndrome is not fully usual [in French]. Ann Pathol. 2006;26(6):445-449.
11. Gahl WA, Brantly M, Troendle J, et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab. 2002;76(3):234-242.
12. Braun JJ, Kessler R, Constantinesco A, Imperiale A. 18F-FDG PET/CT in sarcoidosis management: review and report of 20 cases. Eur J Nucl Med Mol Imaging. 2008;35(8):1537-1543.
13. Young LR, Franz DN, Nagarkatte P, et al. Utility of [18F]2-fluoro-2- deoxyglucose-PET in sporadic and tuberous sclerosisassociated lymphangioleiomyomatosis. Chest. 2009;136(3):926-933.
14. Groves AM, Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50(4):538-545.
15. Wang D, Pascual JM, Yang H, et al. A mouse model for Glut-1 haploinsufficiency. Hum Mol Genet. 2006;15(7):1169-1179.
16. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2004;169(11):1203-1208.
17. El-Chemaly S, Ziegler SG, Calado RT, et al. Natural history of pulmonary fibrosis in two subjects with the same telomerase mutation. Chest. 2011;139(5):1203-1209.
18. Rouhani FN, Brantly ML, Markello TC, et al. Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1. Am J Respir Crit Care Med. 2009;180(11):1114-1121.
19. Jones HA, Clark RJ, Rhodes CG, Schofield JB, Krausz T, Haslett C. In vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med. 1994;149(6):1635-1639.
20. Strieter RM, Gomperts BN, Keane MP. The role of CXC chemokines in pulmonary fibrosis. J Clin Invest. 2007;117(3):549-556.
21. Hanumegowda C, Farkas L, Kolb M. Angiogenesis in pulmonary fibrosis: too much or not enough? Chest. 2012;142(1):200-207.
22. Cosgrove GP, Brown KK, Schiemann WP, et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med. 2004;170(3):242-251.
23. Tzouvelekis A, Harokopos V, Paparountas T, et al. Comparative expression profiling in pulmonary fibrosis suggests a role of hypoxia-inducible factor-1alpha in disease pathogenesis. Am J Respir Crit Care Med. 2007;176(11):1108-1119.
24. Roux-Dalvai F, Gonzalez de Peredo A, Simó C, et al. Extensive analysis of the cytoplasmic proteome of human erythrocytes using the peptide ligand library technology and advanced mass spectrometry. Mol Cell Proteomics. 2008;7(11):2254-2269.
25. Zhang JZ, Ismail-Beigi F. Activation of Glut1 glucose transporter in human erythrocytes. Arch Biochem Biophys. 1998;356(1):86-92.
26. Daskalow K, Pfander D, Weichert W, et al. Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol. 2009;132(1):21-31.
27. Kaira K, Okumura T, Ohde Y, et al. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med. 2011;52(5):705-711.
28. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer. 2002;38(3):261-266.
29. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 1998;39(6):1016-1020.
30. Yap CS, Schiepers C, Fishbein MC, Phelps ME, Czernin J. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging. 2002;29(9):1166-1173.